308 related articles for article (PubMed ID: 22762291)
1. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
3. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
4. Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.
Dretzke J; Round J; Connock M; Tubeuf S; Pennant M; Fry-Smith A; Hulme C; McCabe C; Meads C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):63-70. PubMed ID: 21047493
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
Huse DM; von Mehren M; Lenhart G; Joensuu H; Blanke C; Feng W; Finkelstein S; Demetri G
Clin Drug Investig; 2007; 27(2):85-93. PubMed ID: 17217313
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
8. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
[TBL] [Abstract][Full Text] [Related]
9. Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study).
Mabasa VH; Taylor SC; Chu CC; Moravan V; Johnston K; Peacock S; Knowling M
J Oncol Pharm Pract; 2008 Sep; 14(3):105-12. PubMed ID: 18524863
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
Paz-Ares L; García del Muro X; Grande E; González P; Brosa M; Díaz S
Clin Transl Oncol; 2008 Dec; 10(12):831-9. PubMed ID: 19068454
[TBL] [Abstract][Full Text] [Related]
11. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
Breitscheidel L
J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Blanke CD; Huse DM
J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
[TBL] [Abstract][Full Text] [Related]
14. New fronts in the adjuvant treatment of GIST.
Reichardt P; Joensuu H; Blay JY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.
Hislop J; Quayyum Z; Elders A; Fraser C; Jenkinson D; Mowatt G; Sharma P; Vale L; Petty R
Health Technol Assess; 2011 Jun; 15(25):1-178. PubMed ID: 21689502
[TBL] [Abstract][Full Text] [Related]
16. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.
Gordois A; Scuffham P; Warren E; Ward S
Br J Cancer; 2003 Aug; 89(4):634-40. PubMed ID: 12915870
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Li J; Dang YZ; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
[TBL] [Abstract][Full Text] [Related]
19. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
20. Length of adjuvant imatinib therapy in GIST: weighing benefits, side effects and costs.
Dasanu CA
J Oncol Pharm Pract; 2012 Sep; 18(3):379-80. PubMed ID: 22801957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]